Search

Your search keyword '"L'Allemain, Gilles"' showing total 188 results
Start Over Author "L'Allemain, Gilles"
188 results on '"L'Allemain, Gilles"'

1. Que retenir dans la prise en charge des cancers en 2022 ?

Author

Bay, Jacques-Olivier, Bouleuc, Carole, Caux, Christophe, Delom, Frédéric, Firmin, Nelly, Gandemer, Virginie, L’Allemain, Gilles, Magné, Nicolas, Orbach, Daniel, Robert, Jacques, Rodrigues, Manuel, Sabatier, Renaud, Thiery-Vuillemin, Antoine, and Wislez, Marie

Published
2023
Full Text
View/download PDF

3. Que retenir de l’année 2020 ?

Author

Bay, Jacques-Olivier, Andre, Thierry, Bouleuc, Carole, Gandemer, Virginie, Magne, Nicolas, Orbach, Daniel, Pellier, Isabelle, Penel, Nicolas, Rodrigues, Manuel, Thariat, Juliette, Thiery-Villemin, Antoine, Wisley, Marie, L’Allemain, Gilles, and Robert, Jacques

Published
2021
Full Text
View/download PDF

5. Qu’est-ce que 2023 aura permis de changer dans nos pratiques en cancérologie ?

Author

Bay, Jacques-Olivier, primary, Auberger, Benjamin, additional, Bouleuc, Carole, additional, Cohen, Romain, additional, Delom, Frédéric, additional, Firmin, Nelly, additional, Gandemer, Virginie, additional, L’Allemain, Gilles, additional, Magne, Nicolas, additional, De Nonneville, Alexandre, additional, Orbach, Daniel, additional, Pellier, Isabelle, additional, Rodrigues, Manuel, additional, and Wislez, Marie, additional

Published
2024
Full Text
View/download PDF

11. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Author

Sabatier, Renaud, Vicier, Cécile, Garnier, Séverine, Guille, Arnaud, Carbuccia, Nadine, Isambert, Nicolas, Dalenc, Florence, Robert, Marie, Levy, Christelle, Pakradouni, Jihane, Adelaïde, José, Chaffanet, Max, Sfumato, Patrick, Mamessier, Emilie, Bertucci, François, Goncalves, Anthony, Mezni, Essia, Evans, Catherine Karine, Chinot, Olivier, Loschi, Alain, Arnaud, Sylvie, Mellinas, Marie, Bay, Jacques-Olivier, Bouleuc, Carole, Firmin, Nelly, Gandemer, Virginie, Magne, Nicolas, Orbach, Daniel, Penel, Nicolas, Rodrigues, Manuel, Thiery-Vuillemin, Antoine, Wislez, Marie, L’allemain, Gilles, Robert, Jacques, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen, Monk, Bradley, Oaknin, Ana, Tinker, Anna, Gilbert, Lucy, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, de Nonneville, Alexandre, Zemmour, Christophe, Frank, Sophie, Joly, Florence, Ray-Coquard, Isabelle, Costaz, Hèlène, Classe, Jean-Marc, Floquet, Anne, de La Motte Rouge, Thibault, Colombo, Pierre-Emmanuel, Sauterey, Baptiste, Leblanc, Eric, Pomel, Christophe, Marchal, Frédéric, Barranger, Emmanuel, Savoye, Aude-Marie, Guillemet, Cécile, Petit, Thierry, Pautier, Patricia, Rouzier, Roman, Gladieff, Laurence, Simon, Gaëtane, Courtinard, Coralie, Rousset-Rouviere, Sandrine, Rochigneux, Philippe, Chrétien, Anne-Sophie, Fattori, Stéphane, Gorvel, Laurent, Provansal, Magali, Lambaudie, Eric, Olive, Daniel, Martin, Johan, Guérin, Mathilde, Monneur, Audrey, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Pierga, Jean-Yves, Curé, Hervé, Abulnaja, Rakan, Bidard, François-Clément, Mari, Roxane, Narducci, Fabrice, Cappiello, Maria-Antonietta, Rousseau, Fréderique, Blache, Guillaume, Birnbaum, Daniel, Cropet, C., Montegut, C., Frindte, J., Cinieri, S., Guerra-Alia, E.M., Bogner, G., Yoshida, H., Vergote, I., Hietanen, S., Largillier, R., Canzler, U., Gratet, A., Marmé, F., Pujade-Lauraine, E., Favier, L., Ray-Coquard, I.L., Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, First line, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematology, medicine.disease, Olaparib, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, business, Ovarian cancer, medicine.drug
Abstract

International audience; 5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to assess surgical resectability at diagnosis or after neoadjuvant chemotherapy. However, there is no clinical or biological marker that can correctly predict resectability and may be able to avoid a second laparoscopic exploration for initially unresectable diseases. Our aim was to assess circulating tumor DNA (ctDNA) value as a predictive non-invasive marker of evolution towards resectability for patients with epithelial ovarian cancer receiving first-line chemotherapy. Methods: We explored in this work one of the secondary objectives of the CIDOC study (NCT03302884). CIDOC is a multicenter prospective study aiming to explore ctDNA value as early marker of disease relapse after first-line treatment for epithelial ovarian cancer. Patients with mucinous histology or early stages not requiring chemotherapy are excluded. Plasma samples are collected at diagnosis, during neoadjuvant chemotherapy, and during follow-up. After DNA extraction, panel-based next generation sequencing is performed on both tumor samples and germline DNA, and somatic mutations of interest are selected for ctDNA monitoring. ctDNA analyses are conducted using droplet digital PCR (BioRad QX200) by measuring the variant allele fraction (VAF) of previously identified mutations. Results: This intermediary analysis has included 47 patients diagnosed between March 2017 and December 2019. Median age was 69 years old (48 – 84). Most of the patients had advanced disease (89.4% stage FIGO III or IV), serous histology (94.8%), and high grade tumor (92.3%). Most of the patients underwent complete interval cytoreductive surgery (76.3% vs 17.4% complete upfront surgery). Most of the tumors had TP53 mutations (85.1%), following by alterations involving DNA repair genes (38.3%). Median cell-free DNA concentration at baseline was 0.38 ng/µL (0 – 12.8). ctDNA was identified in 92.1% of patients at baseline with a median VAF of 1.84% (0 – 42.52%). ctDNA VAF was correlated to the peritoneal dissemination ( p= 0.039) assessed with the peritoneal cancer index. ctDNA clearance after preoperative chemotherapy tended to be correlated to achievement of complete interval surgery for patients receiving neoadjuvant chemotherapy ( p= 0.108). Conclusions: ctDNA may be a promising non-invasive marker to assess peritoneal cancer spreading and to predict surgical resectability after neoadjuvant chemotherapy. If confirmed in larger populations, this may enable to avoid additional surgical explorations for patients who remain ctDNA positive after chemotherapy. Clinical trial information: NCT03302884.

Published
2021
Full Text
View/download PDF

15. Freedom, equality, fraternity facing the COVID-19

Author

Bay, Jacques-Olivier, L'Allemain, Gilles, Bodescot, Myriam, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (1965 - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)

Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020
Full Text
View/download PDF

23. Nouvelle année, nouvelles résolutions ? 2019 : quelques changements dans la continuité

Author

Bay, Jacques-Olivier, L’Allemain, Gilles, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), and CHADEYRON, DOMINIQUE

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

24. Mitogen-activated protein kinases P42(mapk) and p44(mapk) are required for fibroblast proliferation

Author

Pages, Gilles, Lenormand, Philippe, L'Allemain, Gilles, Chambard, Jean-Claude, Meloche, Sylvain, and Pouyssegur, Jacques

Subjects
Fibroblasts -- Analysis, Cell differentiation -- Analysis, Protein kinases -- Observations, Science and technology
Abstract

Fibroblast proliferation necessitates the presence of mitogen-activated protein kinases P42 map kinase (mapK) and P44 mapK, which also ensures the change in state of the S phase to G(0) phase during cell differentiation. Inactivation of MAP kinase hinders cell growth and differentiation. It is observed that the expression of any one isoform of MAP kinase RNA antisense results in the suppression of P42 mapK and P44 mapK. The mechanism of suppression is affected through the RNA duplexes formation, as a response to rapid degradation. Protooncogene product Raf-1, a kinase cascade transmitting growth factor, plays role in the activation of MAPK kinase kinase, a MAP kinase activator characterized by dual-specificity.

Published
1993

25. Growth factors induce nuclear translocation of MAP kinases (p42(mapk) and P44(mapk)) but not of their activator MAP kinase kinase (p45(mapkk)) in fibroblasts

Author

Lenormand, Philippe, Sardet, Claude, Pages, Gilles, L'Allemain, Gilles, Brunet, Anne, and Pouyssegur, Jacques

Subjects
Protein kinases -- Physiological aspects, Fibroblasts -- Observations, Cells -- Transplantation, Fibroblast growth factors -- Physiological aspects, Biological sciences
Abstract

Indirect immunofluorescence microscopy was employed to prove that p42mapk and p44mapk which are mitogen-activated protein kinases are responsible for the rapid translocation to the nucleus as a reaction to strong mitogens. Their activator p45mapkk continues to be cytoplasmic. These results support the hypothesis that these kinases have a critical role to play in the transmission of surface receptor-mediated signals to the nucleus.

Published
1993

28. Tributes

Author

Dutreix, Marie, Marty, Michel, Bay, Jacques-Olivier, L’Allemain, Gilles, Vignot, Stéphane, Conception synthèse et étude d'antitumoraux, Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), and Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017
Full Text
View/download PDF

31. Les points chauds de l’actualité en 2017. Une sélection du comité de rédaction du Bulletin du Cancer

Author

Vignot, Stéphane, primary, André, Thierry, additional, Caux, Christophe, additional, Bouleuc, Carole, additional, Evrard, Serge, additional, Gonçalves, Anthony, additional, Lacroix, Magali, additional, Magné, Nicolas, additional, Massard, Christophe, additional, Mazeron, Jean-Jacques, additional, Orbach, Daniel, additional, Rodrigues, Manuel, additional, Thariat, Juliette, additional, Wislez, Marie, additional, L’Allemain, Gilles, additional, and Bay, Jacques-Olivier, additional

Published
2018
Full Text
View/download PDF

34. Hommages

Author

Dutreix, Marie, primary, Marty, Michel, additional, Bay, Jacques-Olivier, additional, L’Allemain, Gilles, additional, and Vignot, Stéphane, additional

Published
2017
Full Text
View/download PDF

35. [Doubling time of progression-free survival by palbociclib in metastatic breast cancer]

Author

L'Allemain, Gilles, Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)

Subjects
MESH: Humans, MESH: Pyridines, MESH: Piperazines, MESH: Antineoplastic Agents, MESH: Clinical Trials, Phase II as Topic, MESH: Female, [SDV.BDD]Life Sciences [q-bio]/Development Biology, ComputingMilieux_MISCELLANEOUS, MESH: Breast Neoplasms
Abstract

International audience

Published
2015

36. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells

Author

RIVARD, NATHALIE, BOUCHER, MARIE-JOSEE, ASSELIN, CLAUDE, and L'ALLEMAIN, GILLES

Subjects
Cell cycle -- Research, Cell research -- Research, Biological sciences
Abstract

Rivard, Nathalie, Marie-Josee Boucher, Claude Asselin, and Gilles L'Allemain. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am. J. Physiol. 277 (Cell Physiol. 46): C652-C664, 1999.--The present report delineates the critical pathway in the [G.sub.1] phase involved in downregulation of [p27.sup.Kip1], a cyclin-dependent kinase inhibitor, which plays a pivotal role in controlling entry into the S phase of the cell cycle. In resting CCL39 fibroblasts and IEC-6 intestinal epithelial cells, protein levels of [p27.sup.Kip1] were elevated but dramatically decreased on serum stimulation, along with hyperphosphorylation of pRb and increased CDK2 activity. In both cell types, expression of ras resulted in an increase of basal and serum-stimulated E2F-dependent transcriptional activity and a reduction in [p27.sup.Kip1] protein levels as well. The role of the mitogen-activated protein (MAP) kinase cascade in [p27.sup.Kip1] reduction and S phase reentry was reinforced by the blockades of serum-induced E2F-dependent transcriptional activity and [p27.sup.Kip1] downregulation with the MKK-1/2 inhibitor PD-98059. In both cell lines, downregulation of [p27.sup.Kip1] was associated with a repression of its synthesis, an event mediated by the p42/p44 MAP kinase pathway. Using an antisense approach, we demonstrated that [p27.sup.Kip1] may control cell cycle exit in both cell types. These data indicate that activation of the MAP kinase cascade is required for S phase entry and [p27.sup.Kip1] downregulation in fibroblasts and epithelial cells. growth control; cell cycle; [G.sub.1]-to-S phase transition; growth signaling

Published
1999

40. État de l'art

Author

Vignot, Stéphane, primary, Bay, Jacques-Olivier, additional, and L'Allemain, Gilles, additional

Published
2016
Full Text
View/download PDF

45. [The year 2013: one hundred years of the publication of Bulletin du Cancer]

Author

Bay, Jacques-Olivier, L'Allemain, Gilles, Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)

Subjects
Protein Structure, Anion Transport, Homology Modeling, SLC4A1, Anion Exchanger 1, Medical Oncology, History, 21st Century, Ion Channels, Band 3, Erythrocyte, MESH: France, stomatognathic diseases, stomatognathic system, France, Periodicals as Topic, MESH: History, 21st Century, [SDV.BDD]Life Sciences [q-bio]/Development Biology, MESH: Medical Oncology, MESH: Periodicals as Topic
Abstract

International audience; The anion exchanger 1 (AE1), a member of bicarbonate transporter family SLC4, mediates an electroneutral chloride/bicarbonate exchange in physiological conditions. However, some point mutations in AE1 membrane-spanning domain convert the electroneutral anion exchanger into a Na(+) and K(+) conductance or induce a cation leak in a still functional anion exchanger. The molecular determinants that govern ion movement through this transporter are still unknown. The present study was intended to identify the ion translocation pathway within AE1. In the absence of a resolutive three-dimensional structure of AE1 membrane-spanning domain, in silico modeling combined with site-directed mutagenesis experiments was done. A structural model of AE1 membrane-spanning domain is proposed, and this model is based on the structure of a uracil-proton symporter. This model was used to design cysteine-scanning mutagenesis on transmembrane (TM) segments 3 and 5. By measuring AE1 anion exchange activity or cation leak, it is proposed that there is a unique transport site comprising TM3-5 and TM8 that should function as an anion exchanger and a cation leak.

Published
2013

48. Éditorial

Author

L’Allemain, Gilles, primary, Vignot, Stéphane, additional, Massard, Christophe, additional, and Bay, Jacques-Olivier, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results